c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

OBJECTIVES: In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Haematol
Autori principali: Di Bacco, Alessandra, Bahlis, Nizar J., Munshi, Nikhil C., Avet‐Loiseau, Hervé, Masszi, Tamás, Viterbo, Luísa, Pour, Ludek, Ganly, Peter, Cavo, Michele, Langer, Christian, Kumar, Shaji K., Rajkumar, S. Vincent, Keats, Jonathan J., Berg, Deborah, Lin, Jianchang, Li, Bin, Badola, Sunita, Shen, Lei, Zhang, Jacob, Esseltine, Dixie‐Lee, Luptakova, Katarina, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317705/
https://ncbi.nlm.nih.gov/pubmed/32145111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13405
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi